HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Important Deadline EstablishedNewsfile Corp • 04/21/21
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.Newsfile Corp • 04/20/21
Rosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGENNewsfile Corp • 04/19/21
Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action LawsuitPRNewsWire • 04/19/21
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the FirmBusiness Wire • 04/19/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline EstablishedPRNewsWire • 04/19/21
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - FGENNewsfile Corp • 04/16/21
FGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against FibroGen Inc.Business Wire • 04/15/21
SHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading ShareholdersBusiness Wire • 04/15/21
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.Business Wire • 04/15/21
FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 04/15/21
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) InvestorsBusiness Wire • 04/14/21
FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.PRNewsWire • 04/14/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts FibroGen (FGEN) Investors to Filing of Securities Fraud Class Action and Encourages Investors with Losses to Contact Its Attorneys NowNewsfile Corp • 04/14/21
SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider TradingPRNewsWire • 04/14/21
BREAKING NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important Deadline - FGENPRNewsWire • 04/14/21
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against FibroGen, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 04/14/21
Berman Tabacco's California Office Files Securities Class Action Lawsuit Against FibroGen, Inc. (FGEN) And Announces June 11, 2021 Lead Plaintiff DeadlineNewsfile Corp • 04/13/21
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the FirmPRNewsWire • 04/13/21
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) InvestorsBusiness Wire • 04/13/21
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important Deadline – FGENBusiness Wire • 04/13/21
Berman Tabacco Files Securities Class Action Lawsuit Against FibroGen, Inc. (FGEN)Newsfile Corp • 04/12/21
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmPRNewsWire • 04/09/21
